Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Avanir Pharmaceuticals Inc Announces Research Collaboration With Department Of Veterans Affairs For Screening Pseudobulbar Affect Symptoms In Veterans With Traumatic Brain Injury


Wednesday, 6 Mar 2013 09:00am EST 

Avanir Pharmaceuticals Inc announced that in collaboration with the Department of Veterans Affairs (VA) and United BioSource Corporation (UBC) announced a pilot study to screen for pseudobulbar affect (PBA) symptoms in approximately 1,000 veterans with traumatic brain injury (TBI) . According to The Bob Woodruff Foundation, it is estimated that more than 320,000 service members have sustained traumatic brain injuries. PBA occurs when a TBI or other neurological condition, such as multiple sclerosis, Lou Gehrig's disease (ALS), Parkinson's disease, stroke or Alzheimer's disease, damages the areas of the brain that controls normal emotional expression, causing uncontrollable episodes of crying or laughing. These outbursts are often contrary or exaggerated to the patient's inner emotional state, causing them to laugh or cry when they may not find the situation to be particularly funny or sad. As a result, many of those afflicted with PBA have impairment on measures of general health status, occupational and social function. People with PBA tend to have higher incidence of depressive symptoms and often avoid social activities they would normally enjoy. 

Company Quote

11.31
0.1 +0.89%
4:00pm EDT